Astatine-211 Labeling of an Antimelanoma Antibody and Its Fab Fragment Using JV-Succinimidyl p-Astatobenzoate: Comparisons in Vivo with the p-[125I]Iodobenzoyl Conjugate

Bioconjugate Chemistry

Volumn 2, Issue 3, 1991, Pages 171-179

  Hadley, Stephen W ^b   Wilbur, D Scott ^a   Gray, Mary Ann ^b,c   Atcher, Robert W ^d  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b Poniard Pharmaceuticals Inc   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d ARGONNE NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTATINE; CANCER ANTIBODY; DIAGNOSTIC AGENT; IMMUNOGLOBULIN FRAGMENT; IMMUNOTOXIN; IODOBENZOIC ACID DERIVATIVE; RADIOACTIVE IODINE;

ANIMAL; ARTICLE; CHEMISTRY; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOLOGY; ISOTOPE LABELING; MALE; MELANOMA; METHODOLOGY; MOUSE; NUDE MOUSE; TISSUE DISTRIBUTION;

ANIMAL; ANTIBODIES, NEOPLASM; ASTATINE; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTOXINS; IODINE RADIOISOTOPES; IODOBENZOATES; ISOTOPE LABELING; MALE; MELANOMA; MICE; MICE, NUDE; SUPPORT, U.S. GOV'T, P.H.S.; TISSUE DISTRIBUTION;

EID: 0026164047     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc00009a006     Document Type: Article

References (50)

1. Hall, E. J. (1988) LET and RBE. Radiobiology for the Radiologist, 3rd ed., Chapter 8, pp 161–177, J.B. Lippincott Comp., Philadelphia, PA.
2. Held, K. D. (1986) Radiobiology: Biological Effects of Ionizing Radiation. Nuclear Medicine Therapy (J. C. Herbert, Ed.) Chapter 17, pp 257–284, Maple-Vail Book Mfg Group, Bing-hampton, NY.
3. Brown, I. (1986) Astatine Radiopharmaceuticals. Astatine-211: Its Possible Applications in Cancer Therapy. Appl. Ra-diat. Isot. 37, 789–798.
4. Zalutsky, M. R. (1989) Antibody-Mediated Radiotherapy: Future Prospects. Antibodies in Diagnosis and Therapy (M. R. Zalutsky, Ed.) Chapter 11, pp 219–225, CRC Press, Inc., Boca Raton, FL.
5. Wilbur, D. S. (1990) Potential Use of Alpha Emitting Radionuclides in the Treatment of Cancer. Antibody, Immunoconjugate Radiopharm. 4, 85–97.
6. Hughes, W. L., and Gitlin, D. (1954) The Reaction of Astatine with Protein, USAECD-BNL-314.
7. 211) Organic Compounds for Production of Highly Localized Radiobiological Effects. Am. Soc. Biol. Chem. 14, 229.
8. Aaij, C., Tschroots, W. R. J. M., Lindner, L., and Feltkamp, T. E. W. (1978) The Preparation of Astatine Labeled Proteins. Int. J. Appl. Radiat. Isot. 26, 25–30.
9. Vaughan, A.T.M., and Fremlin, J.H. (1978) The Preparation of Astatine Labeled Proteins Using an Electrophilic Reaction. Int. J. Nucl. Med. Biol. 5, 229–230.
10. Visser, G. W. M., Diemer, E. L., Vos, C. M., and Kaspersen, F. M. (1981) The Biological Behavior of Some Organic Astatine Compounds in Rats. Int. J. Appl. Radiat. Isot. 32, 913–917.
11. Visser, G. W. M., Diemer, E. L., and Kaspersen, F. M. (1981) The Nature of the Astatine-Protein Bond. Int. J. Appl. Radiat. Isot. 32, 905–912.
12. Friedman, A. M., Zalutsky, M. R., Wung, W., Buckingham, F., Harper, P. V., Jr., Scherr, G. H., Wainer, B., Hunger, R. L., Appelman, E. H., Rotherberg, R. M., Fitch, F. W., Stuart, F. P., and Simonian, S. J. (1977) Preparation of a Biological Stable and Immunogenically Competent Astatinated Protein. Int. J. Nucl. Med. Biol. 4, 219–224.
13. 211At Using an Acylation Reaction. Int. J. Appl. Radiat. Isot. 30, 576–577.
14. 211At Labelled Monoclonal Antibody with Known Specificity in a Murine System. Int. J. Radiat. Oncol. Biol. Phys. 8, 1943–1946.
15. 211At-IgG Conjugate Which is Stable In Vivo. Int. J. Appl. Radiat. Isot. 35, 1005–1008.
16. Meyer, G.-J., Rossler, K., and Stocklin, G. (1979) Reaction of Aromatic Diazonium Salts with Carrier-Free Radioiodine and Astatine. Evidence for Complex Formation. J. Am. Chem. Soc. 101, 3121–3123.
17. Visser, G. W. M., and Diemer, E. L. (1982) The Reaction of Astatine with Aromatic Diazonium Compounds. Radiochem. Radioanal. Lett. 51, 135–141.
18. Milius, R. A., McLaughlin, W. H., Lambrecht, R. M., Wolf, A. P., Carroll, J. J., Adelstein, S. J., and Bloomer, W. D. (1986) Organoastatine Chemistry. Astatination via Electrophilic Destannylation. Appl. Radiat. hot. 37, 799–802.
19. Wilbur, D. S., Hylarides, M. D., and Fritzberg, A. R. (1989) Reactions of Organometallic Compounds with Astatine-211. Application to Protein Labeling. Radiochem. Acta 47, 137–142.
20. Zalutsky, M. R., and Narula, A. S. (1988) Astatination of Proteins Using an N-Succinimidyl Tri-n-butylstannylbenzoate Intermediate. Appl. Radiat. hot. 39, 227–232.
21. 2 with the α-Particle-Emitting Nuclide Astatine-211: Preservation of Immunoreactivity and In Vivo Localizing Capacity. Proc. Natl. Acad. Sci. U.S.A. 86, 7149–7153.
22. Zalutsky, M. R., and Narula, A. S. (1987) An Improved Method for the Radiohalogenation of Monoclonal Antibodies. Immunological Approaches to the Diagnosis and Therapy of Breast Cancer (R. L. Ceriani, Ed.) pp 187–203, Plenum Press.
23. Wilbur, D. S., Hadley, S. W., Hylarides, M. D., Abrams, P. G., Beaumier, P. A., Morgan, A. C., Reno, J. M., and Fritzberg, A. R. (1989) Development of a Stable Radioiodinating Reagent to Label Monoclonal Antibodies for Radiotherapy of Cancer. J. Nucl. Med. 30, 216–226.
24. Eberle, S. H. (1985) Isolation and Purification of Astatine from Irradiated Targets. Gmelin Handbook of Inorganic Chemistry, Astatine, 8th ed. (H. K. Kugler, and C. Keller, Eds.) Chapter 10, pp 199–209, Springer-Verlag, New York.
25. Appelman, E. H., Sloth, E. N., and Studier, M. H. (1966) Observation of Astatine Compounds by Time-of-Flight Mass Spectrometry. Inorg. Chem. 5, 766–769.
26. 211 At. J. Radioanal. Nucl. Chem. Lett. 96, 319–332.
27. Lambrecht, R. M., and Mirzadeh, S. (1985) Cyclotron Isotopes and Radiopharmaceuticals-XXXV. Astatine-211. Int. J. Appl. Radiat. hot. 36, 443–450.
28. Wilbur, D.’S., Hadley, S. W., Hines, J. J., and Atcher, R. W. (1990) Assessment of Dry Distillation Methods for Improving Protein Labeling Yields with Astatine-211. Eighth International Symposium of Radiopharmaceutical Chemistry, Princeton, New Jersey. J. Labelled Compds. Radiopharm. 30, 214–215.
29. 211 (Eka-Iodine) in the Thyroid Gland of Rats and Monkeys. J. Clin. Endocrinol. Metab. 14, 1161–1177.
30. Basson, J. K., and Shellbarger, C. J. (1956) Determination of the RBE of Alpha-Particles from Astatine-211 as Compared to Beta-Particles from Iodine-132 in the Rat Thyroid. Radiat. Res. 5, 502–514.
31. Seiler, F. R., Gronski, P., Kurrle, R., Luben, G., Harthus, H.-P., Ax, W., Bosslet, K., and Schwick, H.-G. (1985) Monoclonal Antibodies: Their Chemistry, Functions, and Possible Uses. Angew. Chem. Int. Ed. Engl. 24, 139–160.
32. Adelstein, S. J., and Kassis, A. I. (1988) Criteria for Selection of Nuclides for Radioimmunotherapy. Radiolabeled Monoclonal Antibodies for Imaging and Therapy (S. C. Srivastava, Ed.) pp 165–176, Plenum Press, New York.
33. Cobb, L. M., and Humm, J. L. (1984) Radioimmunotherapy of Malignancy Using Antibody Targeted Radionuclides. Br. J. Cancer 54, 863–870.
34. Berei, K. and Vasaros, L. (1983) Organic chemistry of astatine. The Chemistry of Functional Groups (S. Patai, and Z. Rappoport, Eds.) Supplement D., Chapter 10, pp 405–440, John Wiley & Sons, Ltd., New York.
35. Brown, I. (1987) Astatine: Its Organonuclear Chemistry and Biomedical Applications. Adv. Inorg. Chem. 31, 43–88.
36. Munzel, H. (1985) Nuclear Properties of Astatine Isotopes. Gmelin Handbook of Inorganic Chemistry, Astatine, 8th ed. (H. K. Kugler, and C. Keller, Eds.) Chapter 3, pp 15–94, Springer-Verlag, New York.
37. Badger, C. C., Wilbur, D. S., Hadley, S.W., Fritzberg, A. R., and Bernstein, I. D. (1990) Biodistribution of p-Iodoben-zoyl (PIP) Labeled Antibodies in a Murine Lymphoma Model. Nucl. Med. Biol. 17, 381–387.
38. Murray, J. L., Mujoo, K., Wilmanns, C., Mansfield, P., Wilbur, D. S., and Rosenblum, M. G. (1991) Variables Influencing Tumor Uptake of Antimelanoma Monoclonal Antibodies Radioiodinated Using the Para-Iodophenyl (PIP) Technique. J. Nucl. Med. 32, 279–287.
39. Wahl, R., Roberts, J., Hopkins, M., Drescher, C., Fig, L., Mallette, S., Mudgett, E., Foisie, D., Schroff, R., Abrams, P., Fer, M., and Wilbur, S. (1990) Phase I Evaluation of I-131 PIP Labeled Anti-Ovarian Carcinoma Antibody. J. Nucl. Med. 31, 777.
40. Coenen, H. H., Moerlein, S. M., and Stocklin, G. (1983) No-Carrier-Added Radiohalogenation Methods with Heavy Halogens. Radiochim. Acta 34, 47–68.
41. Visser, G. W. M., Diemer, E. L., and Kaspersen, F. M. (1979) The Preparation and Stability of Astatotyrosine and Astato-iodotyrosine. Int. J. Appl. Radiat. hot. 30, 749–752.
42. Visser, G. W. M., Diemer, E. L., and Kaspersen, F. M. (1980) The Preparation of Aromatic Astatine Compounds Through Aromatic Mercury Compounds. J. Labelled Compds. Radiopharm. 17, 657–665.
43. Visser, G. W. M., Diemer, E. L., and Kaspersen, F. M. (1981) The Preparation of Aromatic Astatine Compounds Through Aromatic Mercury Compounds Part II: Astatination of Pyrimidines and Steroids. J. Labelled Compds. Radiopharm. 18, 799–807.
44. 211At-astato-imidazoles. Int. J. Appl. Radiat. hot. 31, 275–278.
45. Neirinckx, R. D., and Smit, J. A. (1973) Separation of Astatine-211 from Bismuth Metal. Anal. Chim. Acta 63, 201–204.
46. Ruth, T. J., Dombsky, M., D’Auria, J. M., and Ward, T. E. (1988) Radiochemistry of Astatine, Nuclear Science Series, NAS-NS-3064, Chapter V., pp 41–60, U.S. Department of Energy, Washington, DC.
47. 131I as Labels of a Monoclonal Antibody and F(ab’)2 Fragment. Cancer Res. 50, 3514–3520.
48. Hamilton, J. G., Ashling, C. W., Garrison, W. M., and Scott, K. G. (1953) The Accumulation, Metabolism and Biological Effects of Astatine in Rats and Monkeys. University of California Publications in Pharmacology (H. H. Anderson, D. B. Taylor, and E. L. Way, Eds.) pp 283–343, University of California, Los Angeles.
49. Morgan, A. C., Galloway, D. R., and Reisfeld, R. A. (1981) Production and characterization of a monoclonal antibody to a melanoma specific glycoprotein. Hybridoma 1, 27–36.
50. Giard, D. J., Aaronson, S. A., Todaro, G. J., Arnstein, P., Kersey, J. H., Dosik, H., and Parks, W. P. (1973) In Vitro Cultivation of Human Tumors: Establishment of Cell Lines Derived From a Series of Solid Tumors. J. Natl. Cancer Inst. 51, 1417–1423.